Biotechnology

Sanofi Secures Global Rights to ADEL’s Alzheimer’s Antibody in Deal Worth Up to $1.04 Billion

Targeting acetylated tau, the candidate has entered an FDA-cleared first-in-human trial with Sanofi set to lead later development.